Denali Therapeutics Inc.
Compounds, compositions, and methods

Last updated:

Abstract:

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

Status:
Grant
Type:

Utility

Filling date:

13 Mar 2020

Issue date:

7 Sep 2021